peoplePerson
Pasi A. Jänne
Co-discovered EGFR mutations in lung cancer and has led the drug development that followed, from osimertinib to KRAS G12C inhibitors.
Co-author of the 2004 discovery that EGFR mutations predict gefitinib response; led FLAURA2 (osimertinib plus chemotherapy) and the KRYSTAL-1 adagrasib lung study; directs Dana-Farber's thoracic oncology centre.
Role
Director, Lowe Center for Thoracic Oncology; Director, Belfer Center for Applied Cancer Science
Institution
Specialisms
EGFR-mutant lung cancerTargeted therapy resistanceKRAS G12C
Profiles
| Title | Journal | Year |
|---|---|---|
| Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib | New England Journal of Medicine | 2004 |
| Adagrasib in non-small-cell lung cancer harboring a KRAS G12C mutation | New England Journal of Medicine | 2022 |
| Osimertinib with or without chemotherapy in EGFR-mutated advanced NSCLC | New England Journal of Medicine | 2023 |